COMBINATION OF WHOLE BRAIN RADIOTHERAPY WITH DIFFERENT FRACTION AND CONCOMITANT CAPECITABINE IN BRAIN METASTASIS BREAST CANCER

  • YEOH RUDIYO Department of Radiotherapy, MurniTeguh Memorial General Hospital, Medan, Indonesia
  • JAPARDI ISKANDAR Department of Neurosurgery, Siloam General Hospital, Medan, Indonesia
  • LELO AZNAN Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
  • SUSWORO SUSWORO Department of Radiotherapy, Cipto Mangunkusumo National Central General Hospital, Jakarta, Indonesia
  • PANDELAKI JACUB Department of Radiology, CiptoMangunkusumo National Central General Hospital, Jakarta, Indonesia
  • BACHTIAR ADANG Faculty of Public Health, University of Indonesia, Jakarta, Indonesia
  • ICHWAN MUHAMMAD Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
  • INDHARTY SUZY Department of Neurosurgery, Haji Adam Malik General Hospital, Medan, Indonesia
  • JAMNASI JULI Department of Radiotherapy, MurniTeguh Memorial General Hospital, Medan, Indonesia
  • OMAR WILLIAM Department of Radiotherapy, MurniTeguh Memorial General Hospital, Medan, Indonesia

Abstract

Objective: Breast cancer is the second most frequent cancer worldwide. The main therapeutic modality for breast cancer with brain metastasis is radiation. Whole Brain Radiotherapy (WBRT) is a regional treatment that provides moderate doses of radiotherapy to all brain tissue. Capecitabine was found to be effective for the treatment of breast cancer with metastasis. This study aims to determine the effectiveness of WBRT on the response of breast cancer brain metastatic lesions combined with capecitabine administration.


Methods: This study uses a prospective, randomized-blind cohort analytic study approach. Subjects were randomized into two groups by giving different fraction of WBRT and capecitabine. Subjects were evaluated 4 w post-radiation. Data on differences in patient responses in the two treatment groups were analyzed.


Results: A total of 23 breast cancer patients with brain metastasis participated in this study. Group I (WBRT 10x3Gy + capecitabine 1000 mg/m2/b.i.d) obtained results of 5 (45.5%) out of 11 are responding to therapy. Whereas in group II (WBRT 20x2Gy + capecitabine1000 mg/m2/b.i.d) found 11 (91.7%) out of 12 patients responded to therapy. The results of statistical analysis showed that there were significant differences between the two groups with a value of P = 0.027.


Conclusion: Giving capecitabine and WBRT with 20x2Gy gives a better response both clinically and statistically

Keywords: WBRT, Capecitabine, Breast cancer, Brain metastases

References

1. American Cancer Society. Cancer Treatment and Survivorship Facts and Figures; 2014.
2. Lu J, Steeg PS, Price JE. Breast cancer metastasis: challenges and opportunities. Cancer Res 2009;69:4951-3.
3. Devita H, Rosenbergs. Brain Metastasis. Cancer principles and practice of oncology. 9th edition. Lippincott Williams and Wilkins; 2011.
4. Patchell RA, Regine WF. Brain Metastase: Whole Brain Radiation Therapy Perspective. Principles and Practice of Stereotactic Radiosurgery; 2008. p. 201-5.
5. Rivera E, Meyers C, Groves M. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006;107:1348–54.
6. McEvoy GK. editor. Capecitabine. In: AHFS drug information. Bethesda MD: American Society of Health-System Pharmacists; 2002. p. 916–21.
Statistics
19 Views | 14 Downloads
Citatons
How to Cite
RUDIYO, Y., J. ISKANDAR, L. AZNAN, S. SUSWORO, P. JACUB, B. ADANG, I. MUHAMMAD, I. SUZY, J. JULI, and O. WILLIAM. “COMBINATION OF WHOLE BRAIN RADIOTHERAPY WITH DIFFERENT FRACTION AND CONCOMITANT CAPECITABINE IN BRAIN METASTASIS BREAST CANCER”. International Journal of Current Pharmaceutical Research, Vol. 12, no. 3, May 2020, pp. 107-10, doi:10.22159/ijcpr.2020v12i3.38316.
Section
Original Article(s)